MA27150A1 - Associations pharmaceutiques d'un agoniste de recepteur d'adenosine a2a et d'un agoniste de recepteur adrenergique beta-2 - Google Patents
Associations pharmaceutiques d'un agoniste de recepteur d'adenosine a2a et d'un agoniste de recepteur adrenergique beta-2Info
- Publication number
- MA27150A1 MA27150A1 MA27710A MA27710A MA27150A1 MA 27150 A1 MA27150 A1 MA 27150A1 MA 27710 A MA27710 A MA 27710A MA 27710 A MA27710 A MA 27710A MA 27150 A1 MA27150 A1 MA 27150A1
- Authority
- MA
- Morocco
- Prior art keywords
- receptor agonist
- beta
- adenosine
- pharmaceutical combinations
- adrenergic receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
DEPOSANT Société dite : PFIZER INC. REVENDICATION DE PRIORITES GB 6 Décembre 2001 0129270.5 Voir en annexe le titre de l'invention et le texte de l'abrégé Associations pharmaceutiques d'un agoniste de récepteur d'adénosine A2a et d'un agoniste de récepteur adrénergique (bêta)2 La présente invention concerne une association comprenant (a) un agoniste de récepteur d'adénosine A2a tel que défini dans le présent mémoire et (b) un agoniste de récepteur adrénergique (bêta)2, pour l'administration simultanée, séquentielle ou séparée, par inhalation, dans le traitement d'une maladie obstructive des voies aériennes ou d'une autre maladie inflammatoire.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0129270.5A GB0129270D0 (en) | 2001-12-06 | 2001-12-06 | Pharmaceutical combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27150A1 true MA27150A1 (fr) | 2005-01-03 |
Family
ID=9927164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27710A MA27150A1 (fr) | 2001-12-06 | 2004-06-02 | Associations pharmaceutiques d'un agoniste de recepteur d'adenosine a2a et d'un agoniste de recepteur adrenergique beta-2 |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP1455799B1 (fr) |
| JP (1) | JP2005513041A (fr) |
| KR (1) | KR100685557B1 (fr) |
| CN (1) | CN1856314A (fr) |
| AP (2) | AP2004003082A0 (fr) |
| AR (1) | AR037634A1 (fr) |
| AT (1) | ATE293982T1 (fr) |
| AU (1) | AU2002351066B2 (fr) |
| BR (1) | BR0214998A (fr) |
| CA (1) | CA2469085A1 (fr) |
| CO (1) | CO5580752A2 (fr) |
| DE (1) | DE60203934T2 (fr) |
| DK (1) | DK1455799T3 (fr) |
| EA (1) | EA200400639A1 (fr) |
| EC (1) | ECSP045132A (fr) |
| ES (1) | ES2239728T3 (fr) |
| GB (1) | GB0129270D0 (fr) |
| GT (1) | GT200200258A (fr) |
| HN (1) | HN2002000348A (fr) |
| HR (1) | HRP20040517A2 (fr) |
| HU (1) | HUP0402540A3 (fr) |
| IS (1) | IS7280A (fr) |
| MA (1) | MA27150A1 (fr) |
| MX (1) | MXPA04005506A (fr) |
| NO (1) | NO20042839L (fr) |
| NZ (1) | NZ533054A (fr) |
| OA (1) | OA12738A (fr) |
| PA (1) | PA8560701A1 (fr) |
| PE (1) | PE20030834A1 (fr) |
| PL (1) | PL370739A1 (fr) |
| PT (1) | PT1455799E (fr) |
| PY (1) | PY0228254A (fr) |
| SV (1) | SV2004001426A (fr) |
| TN (1) | TNSN04101A1 (fr) |
| TW (1) | TWI256388B (fr) |
| UY (1) | UY27566A1 (fr) |
| WO (1) | WO2003047598A1 (fr) |
| ZA (1) | ZA200403966B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100785969B1 (ko) * | 2004-05-12 | 2007-12-14 | 동아제약주식회사 | Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제 |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| AU2013388034B2 (en) | 2013-04-30 | 2019-08-15 | Aspeya US Inc. | Dry powder formulations and methods of use |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| JP7493449B2 (ja) | 2017-09-22 | 2024-05-31 | ヴェクチュラ インコーポレイテッド | ステアリン酸マグネシウムを含む乾燥粉末組成物 |
| WO2022050230A1 (fr) * | 2020-09-03 | 2022-03-10 | 学校法人埼玉医科大学 | Composition inhibant l'activation d'un récepteur de l'adénosine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003960D0 (en) * | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| TWI227240B (en) * | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
-
2001
- 2001-12-06 GB GBGB0129270.5A patent/GB0129270D0/en not_active Ceased
-
2002
- 2002-11-14 PY PY200200228254A patent/PY0228254A/es unknown
- 2002-11-28 OA OA1200400164A patent/OA12738A/en unknown
- 2002-11-28 PL PL02370739A patent/PL370739A1/xx not_active Application Discontinuation
- 2002-11-28 CA CA002469085A patent/CA2469085A1/fr not_active Abandoned
- 2002-11-28 CN CNA028244168A patent/CN1856314A/zh active Pending
- 2002-11-28 DE DE60203934T patent/DE60203934T2/de not_active Expired - Fee Related
- 2002-11-28 EA EA200400639A patent/EA200400639A1/ru unknown
- 2002-11-28 NZ NZ533054A patent/NZ533054A/en unknown
- 2002-11-28 BR BR0214998-2A patent/BR0214998A/pt not_active IP Right Cessation
- 2002-11-28 HU HU0402540A patent/HUP0402540A3/hu unknown
- 2002-11-28 PT PT02785778T patent/PT1455799E/pt unknown
- 2002-11-28 AP APAP/P/2004/003082A patent/AP2004003082A0/en unknown
- 2002-11-28 EP EP02785778A patent/EP1455799B1/fr not_active Expired - Lifetime
- 2002-11-28 JP JP2003548853A patent/JP2005513041A/ja active Pending
- 2002-11-28 ES ES02785778T patent/ES2239728T3/es not_active Expired - Lifetime
- 2002-11-28 AP APAP/P/2004/003053A patent/AP2004003053A0/en unknown
- 2002-11-28 MX MXPA04005506A patent/MXPA04005506A/es active IP Right Grant
- 2002-11-28 WO PCT/IB2002/005057 patent/WO2003047598A1/fr not_active Ceased
- 2002-11-28 KR KR1020047008609A patent/KR100685557B1/ko not_active Expired - Fee Related
- 2002-11-28 AU AU2002351066A patent/AU2002351066B2/en not_active Ceased
- 2002-11-28 AT AT02785778T patent/ATE293982T1/de not_active IP Right Cessation
- 2002-11-28 DK DK02785778T patent/DK1455799T3/da active
- 2002-11-28 HR HR20040517A patent/HRP20040517A2/hr not_active Application Discontinuation
- 2002-11-29 TW TW091134818A patent/TWI256388B/zh not_active IP Right Cessation
- 2002-12-03 HN HN2002000348A patent/HN2002000348A/es unknown
- 2002-12-03 PE PE2002001164A patent/PE20030834A1/es not_active Application Discontinuation
- 2002-12-04 AR ARP020104685A patent/AR037634A1/es unknown
- 2002-12-05 UY UY27566A patent/UY27566A1/es not_active Application Discontinuation
- 2002-12-05 SV SV2002001426A patent/SV2004001426A/es not_active Application Discontinuation
- 2002-12-05 GT GT200200258A patent/GT200200258A/es unknown
- 2002-12-06 PA PA20028560701A patent/PA8560701A1/es unknown
-
2004
- 2004-05-21 ZA ZA200403966A patent/ZA200403966B/xx unknown
- 2004-05-21 IS IS7280A patent/IS7280A/is unknown
- 2004-06-02 MA MA27710A patent/MA27150A1/fr unknown
- 2004-06-03 CO CO04052108A patent/CO5580752A2/es not_active Application Discontinuation
- 2004-06-04 TN TNP2004000101A patent/TNSN04101A1/fr unknown
- 2004-06-04 EC EC2004005132A patent/ECSP045132A/es unknown
- 2004-07-05 NO NO20042839A patent/NO20042839L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dursun et al. | Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic caseseries outcome study | |
| Langley et al. | Nimodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease | |
| Badawy | Tryptophan: the key to boosting brain serotonin synthesis in depressive illness | |
| TNSN01053A1 (fr) | Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique | |
| EP1790340A3 (fr) | Chimotherapie combinée | |
| Montgomery et al. | Profiles of antidepressant activity with the montgomery‐asberg depression rating scale | |
| Karlsson et al. | A randomised, double‐blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia | |
| EP2087891A3 (fr) | Compositions pharmaceutiques pour le traitement du lymphome | |
| MA29378B1 (fr) | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer | |
| BRPI0418270A (pt) | métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica | |
| SG127739A1 (en) | Use of immuno-regulators | |
| BR0012793A (pt) | Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina | |
| MXPA03008955A (es) | Agente terapeutico para enfermedades de tipo artritides cronicas o enfermedades relacionadas con la ninez. | |
| MY145074A (en) | Thiazolidin-4-one derivatives | |
| NO932010D0 (no) | Vaksine for neisseria meningitidis infeksjoner | |
| MA29723B1 (fr) | Composes | |
| White et al. | Serotonin-uptake inhibitors in obsessive-compulsive disorder: a case report | |
| MA27150A1 (fr) | Associations pharmaceutiques d'un agoniste de recepteur d'adenosine a2a et d'un agoniste de recepteur adrenergique beta-2 | |
| MA30901B1 (fr) | Therapie de combinaison sequentielle | |
| MA27059A1 (fr) | Azithromycine en dose unique | |
| Steiner et al. | Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. | |
| CA2528312A1 (fr) | Procedes de gestion des symptomes du syndrome premenstruel | |
| MA27152A1 (fr) | Association d'un inhibiteur de pde4 selectif et d'un agoniste de recepteur beta-2 adrenergique | |
| EE200100689A (et) | IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon | |
| MA28121A1 (fr) | Agent immunothérapique utile pour le traitement combiné de la tuberculose en association avec d'autres médicaments |